Samuel James Longo, PT, DPT | |
3607 Raftersridge Dr, Midlothian, VA 23113-3747 | |
(516) 459-9288 | |
Not Available |
Full Name | Samuel James Longo |
---|---|
Gender | Male |
Speciality | Physical Therapist |
Location | 3607 Raftersridge Dr, Midlothian, Virginia |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1386217172 | NPI | - | NPPES |
2305213946 | Other | VA | PHYSICAL THERAPY LICENSE |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208100000X | Physical Medicine & Rehabilitation | 2305213946 (Virginia) | Secondary |
225100000X | Physical Therapist | 2305213946 (Virginia) | Primary |
Mailing Address | Practice Location Address |
---|---|
Samuel James Longo, PT, DPT 3607 Raftersridge Dr, Midlothian, VA 23113-3747 Ph: (516) 459-9288 | Samuel James Longo, PT, DPT 3607 Raftersridge Dr, Midlothian, VA 23113-3747 Ph: (516) 459-9288 |
News Archive
Smokers who lie about their habit to their doctors could in future be caught out by a simple blood test.
Connecticut now has more health benefit mandates than nearly all other states, a consultant told a state board Thursday. And when federal health reform rolls out in just over two years, that could leave the state, not the insurers, with a bill to pay. ... Although it's not yet clear what benefits federal government will require, as many as three-quarters of the benefits that Connecticut mandates could exceed what the federal government requires.
HemoShear LLC, a biotechnology research company and leading developer of human cell-based surrogate systems for discovery and assessment of new drug compounds, today announced that the U.S. Patent and Trademark Office (USPTO) has granted it patent no. 7,811,782 entitled "Use of An In Vitro Hemodynamic Endothelial/Smooth Muscle Cell Co-Culture Model to Identify New Therapeutic Targets for Vascular Disease."
The debate about using menopausal hormone therapies to relieve symptoms in post-menopausal women has been ongoing. Is the combination therapy of estrogen and progestin better or worse than just giving women estrogen alone? In women who still have a uterus (those who have not had a hysterectomy), progestin counteracts the increased risk of uterus cancer when estrogen is given alone, but at the expense of an increase in breast cancer risk compared to estrogen alone.
› Verified 2 days ago